1:07 PM
 | 
Aug 16, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Amylyx begins Phase II of AMX0035 for ALS

Amylyx Pharmaceutical Corp. (Cambridge, Mass.) began the Phase II CENTAUR trial to evaluate twice-daily oral AMX0035 for 24 weeks in 132 patients with amyotrophic lateral sclerosis (ALS).

The double-blind, placebo-controlled, U.S. trial will evaluate...

Read the full 150 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >